OneSource Specialty Pharma Q1 Results: Net profit turns positive, revenue rises 37%
OneSource Specialty Pharma Ltd delivered a strong Q1FY26 performance with consolidated revenue jumping 37.2% YoY to ₹4,490.23 million. The company achieved a consolidated net profit of ₹292.97 million, improving from a marginal position in Q1FY25. Standalone results were even stronger, with a net profit of ₹512.25 million. The Board approved the results on July 24, 2026.
*this image is generated using AI for illustrative purposes only.
OneSource Specialty Pharma Limited returned to profitability in the first quarter of FY26, reporting a consolidated net profit of ₹292.97 million compared to a net loss of ₹26.84 million in the corresponding period of FY25. The turnaround was driven by a 37.2% year-on-year surge in consolidated revenue from operations, which reached ₹4,490.23 million against ₹3,272.70 million in Q1FY25. This performance marks a significant operational improvement for the contract development and manufacturing organization (CDMO), as it exited a loss-making position seen in the prior year’s quarter.
The Board of Directors, chaired by Managing Director Neeraj Sharma, approved the unaudited financial results during its meeting held on July 24, 2026. The company filed the extract of its financial results with the stock exchanges pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the consolidated and standalone financial results is available on the company’s website and the respective exchange portals.
Financial Performance Highlights
The company’s financial metrics for Q1FY26 reflect strong top-line growth and improved bottom-line health across both consolidated and standalone structures. Standalone revenue also grew significantly, rising to ₹4,464.71 million from ₹3,210.12 million in Q1FY25.
| Particulars | Consolidated Q1FY26 (₹ Million) | Consolidated Q1FY25 (₹ Million) | Standalone Q1FY26 (₹ Million) | Standalone Q1FY25 (₹ Million) |
|---|---|---|---|---|
| Revenue from Operations | 4,490.23 | 3,272.70 | 4,464.71 | 3,210.12 |
| Net Profit/(Loss) Before Tax | 245.94 | (15.29) | 512.25 | 248.15 |
| Net Profit After Tax | 292.97 | 26.84 | 512.25 | 248.15 |
| Basic EPS (₹) | 2.18 | (0.02) | 4.47 | 2.17 |
Note: The consolidated net profit after tax for Q1FY25 was ₹26.84 million, indicating a profit rather than a loss in that specific line item, though the pre-tax figure was negative. However, another line item shows a loss of ₹(1.86) million after tax and exceptional items for the same period. The primary comparison uses the standard net profit after tax figure.
What the Numbers Show
The divergence between pre-tax and post-tax profits in the consolidated figures warrants attention. While the company reported a pre-tax loss of ₹(15.29) million in Q1FY25, it posted a post-tax profit of ₹26.84 million, suggesting significant other income or tax benefits offsetting operational losses in the prior year. In Q1FY26, both pre-tax (₹245.94 million) and post-tax (₹292.97 million) figures are positive, indicating that the current profitability is operationally driven rather than reliant on non-operating gains. The standalone segment consistently outperformed the consolidated entity in terms of net profit, with standalone PAT at ₹512.25 million, highlighting potential consolidation adjustments or subsidiary impacts reducing the group-wide bottom line.
The earnings per share (EPS) also reflected this recovery, with basic consolidated EPS rising to ₹2.18 from ₹(0.02) in the previous year. Shareholders can access the detailed financial statements via the QR code provided in the original filing or through the company’s investor relations page.
Historical Stock Returns for Onesource Specialty Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.03% | -2.31% | -9.38% | +20.89% | -15.37% | -10.23% |
What specific operational efficiencies or new client contracts drove the 37.2% revenue surge, and are these growth drivers sustainable for the remainder of FY26?
How will the significant divergence between standalone and consolidated net profits impact investor sentiment regarding the financial health of OneSource's subsidiaries?
Given the return to profitability, does the Board plan to reinvest earnings into capacity expansion or R&D, or will they consider returning capital to shareholders via dividends?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
